These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
49. Evaluation of cardiotoxicity of anthracycline-containing chemotherapy regimens in patients with bone and soft tissue sarcomas: A study of the FDA adverse event reporting system joint single-center real-world experience. Mo Z; Deng Y; Bao Y; Liu J; Jiang Y Cancer Med; 2023 Dec; 12(24):21709-21724. PubMed ID: 38054208 [TBL] [Abstract][Full Text] [Related]
51. Anthracycline-Induced Cardiotoxicity: Causes, Mechanisms, and Prevention. Bhagat A; Kleinerman ES Adv Exp Med Biol; 2020; 1257():181-192. PubMed ID: 32483740 [TBL] [Abstract][Full Text] [Related]
52. Anthracycline Chemotherapy-Induced Cardiotoxicity in Breast Cancer Survivors: A Systematic Review. Lin KJ; Lengacher CA Oncol Nurs Forum; 2019 Sep; 46(5):E145-E158. PubMed ID: 31424455 [TBL] [Abstract][Full Text] [Related]
53. Does anthracycline-based chemotherapy in pregnant women with cancer offer safe cardiac and neurodevelopmental outcomes for the developing fetus? Framarino-Dei-Malatesta M; Sammartino P; Napoli A BMC Cancer; 2017 Nov; 17(1):777. PubMed ID: 29162041 [TBL] [Abstract][Full Text] [Related]
54. Cardiotoxicity screening of long-term, breast cancer survivors-The CAROLE (Cardiac-Related Oncologic Late Effects) Study. Puckett LL; Saba SG; Henry S; Rosen S; Rooney E; Filosa SL; Gilbo P; Pappas K; Laxer A; Eacobacci K; Kapyur AN; Robeny J; Musial S; Chaudhry A; Chaudhry R; Lesser ML; Riegel A; Ramoutarpersaud S; Rahmani N; Shah A; Papas V; Dawodu T; Charlton J; Knisely JPS; Lee L Cancer Med; 2021 Aug; 10(15):5051-5061. PubMed ID: 34245128 [TBL] [Abstract][Full Text] [Related]
55. Anthracycline-induced cardiotoxicity - are we about to clear this hurdle? Dempke WCM; Zielinski R; Winkler C; Silberman S; Reuther S; Priebe W Eur J Cancer; 2023 May; 185():94-104. PubMed ID: 36966697 [TBL] [Abstract][Full Text] [Related]
56. [Pathogenesis, prevention and detection of cardiotoxicity of anthracycline cytostatic agents]. Mladosievicová B; Hulín I; Krcméry V; Petrásová H; Kollárová H Bratisl Lek Listy; 1994 Jul; 95(7):304-22. PubMed ID: 7812833 [TBL] [Abstract][Full Text] [Related]
57. Cardiotoxicity in anthracycline therapy: Prevention strategies. Cruz M; Duarte-Rodrigues J; Campelo M Rev Port Cardiol; 2016 Jun; 35(6):359-71. PubMed ID: 27255173 [TBL] [Abstract][Full Text] [Related]
58. Biomarkers for the early detection of anthracycline-induced cardiotoxicity: current status. Horacek JM; Vasatova M; Pudil R; Tichy M; Zak P; Jakl M; Jebavy L; Maly J Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2014 Dec; 158(4):511-7. PubMed ID: 24457832 [TBL] [Abstract][Full Text] [Related]
59. [Cardiooncology: Current Aspects of Prevention of Anthracycline Toxicity]. Vasyuk YA; Shkolnik EL; Nesterov VV; Shkolnik LD; Varlan GV Kardiologiia; 2016 Dec; 56(12):72-79. PubMed ID: 28290807 [TBL] [Abstract][Full Text] [Related]
60. Body Surface Area and Baseline Blood Pressure Predict Subclinical Anthracycline Cardiotoxicity in Women Treated for Early Breast Cancer. Kotwinski P; Smith G; Cooper J; Sanders J; Ma L; Teis A; Kotwinski D; Mythen M; Pennell DJ; Jones A; Montgomery H; PLoS One; 2016; 11(12):e0165262. PubMed ID: 27911951 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]